Phase 3
Completed N=136
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
Active Rheumatoid Arthritis
Source: ClinicalTrials.gov NCT03172325 ↗
Enrolled (actual)
136
Serious AEs
2.2%
Results posted
Feb 2021
Primary outcomePrimary: Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24 — 63; 63 percentage of participants
◆ Published Evidence
Established
33citations · ~4 / year
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Summary
The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis. Patients with the diagnosis of active Rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years will be included. This study is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active-controlled non-inferiority clinical trial. The eligible patients are randomized in a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.
The primary objective of the study is to compare the efficacy of test- adalimumab (CinnoRA®) and the reference adalimumab (Humira®) in patients with moderately to severely active rheumatoid arthritis regarding the evaluation of EULAR criteria based on Disease activity score (DAS).
The secondary objectives of this study are:
* To further compare the efficacy of test- adalimumab to reference adalimumab
* To assess the safety of test- adalimumab compared to reference adalimumab
Linked Publications
-
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24 |
63; 63 | — |
| SECONDARY Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24 |
92; 89; 77; 75; 47; 53 | — |
| SECONDARY Health Assessment Questionnaire (HAQ) Disability Index at Week 24. |
0.25; 0.19 | — |
| SECONDARY The Incidence of Adverse Events |
23; 30 | — |
| SECONDARY Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) |
5; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female aged 18-75 years at the time of signing the informed consent form.
- Have been diagnosed as having active rheumatoid arthritis (RA) according to The European League Against Rheumatism criteria
- moderately to severely active RA for at least six months
- Patients who have an inadequate response to the treatment with the usual non-biological regimen for at least 12 weeks according to their investigator judgment.
- Ability to comprehend and willingness to sign the Informed Consent Form for this study.
Exclusion Criteria
- Tuberculosis patient or latent tuberculosis patient (PPD >5mm or abnormal Chest X-ray)
- Have been treated previously with any biological agents including any tumor necrosis factor inhibitors (including ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), SIMPONI® (golimumab), or Adalimumab).
- Have a known hypersensitivity to human immunoglobulin proteins or other components of Humira or test- Adalimumab
- Women who are pregnant, breastfeeding or planning to become pregnant during the study
- Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus (HIV) of the past three months.
- Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound)
- Have had a serious infection or have been treated with intravenous antibiotics for an infection within eight weeks or oral antibiotics within two weeks prior to screening
- Have a history of chronic or recurrent infection
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > two times upper limit of normal.
- Hemoglobin 2 mg/dl
- Concomitant use of Prednisolone > 10 mg/day and NSAIDs
- Treatment with intravenous, intramuscular, intra-articular and oral corticosteroids within four weeks prior to Day 1 (prednisolone, more than 7.5 mg/daily)
- Ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
- Have any of the following conditions:
- History of congestive heart failure.
- History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening.
- History of demyelinating disorders (e.g., MS)
- History of multiple sclerosis
- History of any malignancy within the previous five years prior to Screening.
- Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.
Data sourced from ClinicalTrials.gov (NCT03172325) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.